Saturday February 16, 2019 04:49

Heathcare Press Release : 15 Sep 2015

EASD: Additional Evidence Showed ABASAGLAR(R) (insulin glargine) Provided Safety and Efficacy Heathcare—15 Sep 15

- Secondary analyses evaluated ABASAGLAR(R) in patients previously treated with Lantus(R) insulin glargine Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR(R) (insulin glargine), Eli Lilly and Company and Boehringer

New Xultophy(R) (IDegLira) Phase 3b Trial Shows Improvements in Patient-Reported Outcomes Versus Heathcare—15 Sep 15

This material is intended for global medical media only. For journalistic assessment and preparation before publication. New findings from the DUAL(TM) V phase 3b clinical trial showed greater improvements in treatment-related satisfaction and

New Data Confirm Tresiba(R) U200 Delivers Significantly Lower Rates of Confirmed Hypoglycaemia Heathcare—15 Sep 15

New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba(R) (insulin degludec) experienced significantly lower rates

New Study Shows Different Perceptions of Control Among Physicians and Patients May Lead to Heathcare—15 Sep 15

Results presented today at the European Association for the Study of Diabetes (EASD) showed that increased awareness about how patients' and physicians' perceptions of control differ, could benefit physician-patient communication and improve diabetes

New Data on Saxenda(R) Show Early Response Predicts Improvements in Weight Loss and Cardiometabolic Heathcare—15 Sep 15

Today, new data from a post-hoc analysis of the phase 3a SCALE(TM) clinical development programme were presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting.[1] The data demonstrated that adults in the SCALE(TM)